Pharma Spending Growth Rate May Never Reach 'Boom' of '00-'01, Bruker CEO Says | GenomeWeb
NEW YORK (GenomeWeb News) – The rate of growth at which drug makers invest in life science tools and technologies may never reach the levels seen during the 2000 or 2001 “boom,” according to Bruker BioSciences CEO Frank Laukien.
 
“It’s certainly better than it has been [recently] but may never again be at the 2000-2001 levels,” Laukien said during a break-out session following his presentation at the UBS Life Sciences Conference here today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.